![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Genetic Analysis’s GA-map Dysbiosis Test for Microbiome Gains CE Mark
Genetic Analysis’s GA-map Dysbiosis Test for Microbiome Gains CE Mark
February 8, 2022
Oslo, Norway-based Genetic Analysis has received a CE mark for its GA-map microbiome test for the Luminex MAGPIX instrument system.
The test generates a profile of a person’s gut flora and connects the profile to the patient’s health conditions, including irritable bowel syndrome, inflammatory bowel disease, type 2 diabetes, gut disorder (gastrointestinal problems), lifestyle diseases and leaky-gut syndrome.
The test previously earned a CE mark for use with the Luminex LX200 system. The GA-map’s availability for the lower-cost Luminex MAGPIX system will allow more users to install the test platform, the company said.
Upcoming Events
-
21Oct